Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Antiviral Res. 2017 Jan 10;140:45–54. doi: 10.1016/j.antiviral.2017.01.006

Fig. 3. Survival curves and body weight changes for compound 3 (A and B), amantadine (1) (C and D), and oseltamivir (4) in p.o. treatment of an influenza A/Solomon Islands/3/2006 (H1N1) virus infection in mice.

Fig. 3

(A) Survival curves for compound 3. (B) Body weight changes for compound 3. (C) Survival curves for amantadine (1). (D) Body weight changes for amantadine (1). Oral gavage treatments were given twice a day for 5 days starting 30 min before virus exposure at day 0. *** P<0.001 compared to placebo, determined by the Mantel-Cox log-rank test with pairwise comparisons made by the Gehan-Breslow-Wilcoxon test. Groups of 10 compound-treated mice and 20 placebos were used. Groups of 10 compound-treated mice and 20 placebos were used. Mean values are shown at each time point. Error bars are not shown because animals were weighed as groups instead of individually in this experiment.